Clinical Trial Update: A Study of Brentuximab Vedotin in Combination With Cyclophosphamide, Doxorubicin (Hydroxydaunorubicin), Prednisone (CHP) in Chinese Participants With CD30-Positive (CD30+) Peripheral T-Cell Lymphomas (PTCL) [Phase 2]

View source ↗

Summary

A Phase 2 trial of Brentuximab vedotin in combination with CHP for CD30-positive Peripheral T-Cell Lymphoma in Chinese participants is currently active but not …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peripheral T-cell Lymphoma

Drugs mentioned

• Brentuximab vedotin (Brentuximab vedotin)

Snippet

Sponsor: Takeda | Conditions: Lymphoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING